Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

Abstract Background A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose...

Full description

Bibliographic Details
Main Authors: Metalia Puspitasari, Prenali D. Sattwika, Auliana R. P. Hidayat, Wynne Wijaya, Yulia Wardhani, Umi S. Intansari, Nyoman Kertia, Bambang Purwanto, Jarir At Thobari
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Nephrology
Subjects:
COVID-19 vaccines
Booster
End-stage renal disease
Haemodialysis
Immunogenicity
Safety
Online Access:https://doi.org/10.1186/s12882-023-03218-x

Internet

https://doi.org/10.1186/s12882-023-03218-x

Similar Items